Regenerative Medicine

Regenerative medicine, at the interface of engineering and life sciences, exploits (the properties of) living cells, in combination with biomaterials, molecular agents or genes, to repair or replace damaged tissues and organs. Its revolutionary potential is to restore or establish normal body function by using the regenerative capacity of the body itself.

Building on our strengths in biomedical engineering and materials sciences, the main focus at TU/e is on materials-based tissue engineering approaches for cardiovascular and orthopedic applications, where the regenerative capacity of the body itself is stimulated and modulated. As a part of this, we use our engineering skills to design computational models and in-vitro engineered tissue models (tissues-on-chip) that deepen our understanding of tissue development, malformation (including cancer), degeneration and regeneration. Computer simulations and diagnostic data are used to support the development of precise, timely and effective treatments with predicted outcomes.

Challenges & breakthroughs

  • To seduce the body to regenerate itself, recapitulating developmental processes through bio-inspired techniques
  • To regenerate tissue without further medication or treatment: ‘one intervention for life’
  • To develop minimally invasive, painless and (cost-)effective regenerative treatments

Roadmap

Our main focus is on load-bearing tissues that have a biomechanical function. The level of complexity increases over time and with the target organ: starting with science and technology development for tissue regeneration in tissues with simple composition and geometries (e.g. vessels, cartilage), towards more complex tissue and organ geometries (e.g. heart valves, bones), and complex organ systems consisting of multiple tissue types (e.g. the heart, intervertebral disc). At all levels of complexity we aim to cover the complete biomedical research pipeline from scientific idea, to proof of concept, up to first-in-man application.

Projects

For example:

  • EU FP7 project ImaValve
  • EU FP7 project LifeValve
  • EU FP7 Marie Curie INT project TECAS
  • ZonMw 2-treat InSiTeVx
  • Netherlands Institute of Regenerative Medicine (NiRM)
  • AOSpine International project Notochordal Cell Technology
  • EU FP7 project bonECMonitor
  • ERC project REMOTE
  • InSciTe Biomedical Materials project SynCart
  • InSciTe Biomedical Materials project XS-Graft
  • LSH Impulse MIGRATE
  • LSH Impulse iValve-II
  • CVON 1Valve
  • CVON REMAIN

Partners

Among others:

  • Utrecht University and UMC Utrecht
  • Leiden UMC
  • AMC
  • Maastricht University and MUMC+
  • EUR and Erasmus Medical Center
  • Radboud University Nijmegen
  • Twente University
  • University Hospital and University Zurich, Switzerland
  • Wyss Translational Center Zurich
  • ETH Zurich
  • Ort Braude College of Engineering
  • RWTH Aachen
  • McGill University
  • Philips
  • TNO
  • Xeltis
  • Lifetec Group
  • Symo-Chem
  • Suprapolix
  • DSM Biomedical
  • Hartstichting
  • Nierstichting
  • Reumafonds

Contact

For questions or more information about this research, please contact theme leader prof.dr. Carlijn Bouten.